Title: Oprah Winfrey Steps Down from WeightWatchers Board After Using Weight-Loss Drug
After a decade of service on the WeightWatchers board, media mogul Oprah Winfrey has decided to step down from her position. The 70-year-old announced this decision at the annual shareholders meeting, revealing that she will not seek reelection in May 2024. This announcement follows Oprah’s admission a few months ago that she is currently using an undisclosed weight-loss drug.
Oprah’s Decision to Step Down
Oprah Winfrey, in a recent statement, expressed her commitment to continuing to advise and collaborate with WeightWatchers and CEO Sima Sistani. She aims to raise awareness about obesity as a chronic condition, reduce stigma, and advocate for health equity. Additionally, Oprah plans to donate her shares in the company to the National Museum of African American History and Culture. Since acquiring a 10% stake in 2015, Oprah has been an influential voice on the company’s board.
The Impact of Oprah’s Departure
WeightWatchers’ Chairman of the Board, Thilo Semmelbauer, praised Oprah as an inspiring presence and dedicated advocate for all members. He emphasized the valuable contributions Oprah has made to the board and expressed regret over her impending departure.
Oprah’s Weight-Loss Journey
In an exclusive interview with PEOPLE in 2023, Oprah Winfrey discussed her decision to turn to weight-loss medication. She emphasized that weight management goes beyond self-control and acknowledged the importance of medically approved solutions. Oprah’s openness about her weight-loss journey reflects a shift in perspective on health and well-being.
Evolution of WeightWatchers
WeightWatchers has adapted its program to accommodate individuals using prescription medications for weight loss, reflecting a growing trend in the industry. However, Oprah’s revelation about her weight-loss drug choice sparked a broader conversation about Hollywood’s embrace of such medications, particularly Ozempic.
Hollywood’s Embrace of Weight-Loss Medications
Celebrities like Chelsea Handler, Sharon Osbourne, and Kelly Osbourne have publicly acknowledged using Ozempic or Wegovy for weight management. The rising popularity of these drugs has led to a global shortage, impacting individuals with Type 2 diabetes who rely on them for treatment.
By stepping down from the WeightWatchers board, Oprah Winfrey continues to be a trailblazer in the health and wellness industry. Her transparency about her weight-loss journey and advocacy for health equity highlight the importance of addressing obesity as a chronic condition.